Condition: Rectal Cancer · Sponsor: University of Kansas Medical Center
The primary aims of this study is to characterize exosomal biomarker levels in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation therapy. Compare rates of exosomal expression before during and after chemoradiation therapy with pathologic response rates at the time of APR or LAR. The researchers will also examine the functionality of these exosomes in malignant colonic organoids and mouse models of colorectal cancer.
This description comes directly from the study's public registry record.
Leah K Miller, MS · 913-588-3670 · lmiller25@kumc.edu
Michelle Faucheux, RN · 913-588-9927 · mfaucheux@kumc.edu
Always discuss trial participation with your own doctor first.
| University of Kansas Medical Center/ Cancer Center | Kansas City, Kansas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03874559